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a b s t r a c t
Alternative splicing (AS) plays an important role in regulating mammalian heart development, but a link
between misregulated splicing and congenital heart defects (CHDs) has not been shown. We reported that
more than 50% of genes associated with heart development were alternatively spliced in the right ventricle
(RV) of infants with tetralogy of Fallot (TOF). Moreover, there was a signiﬁcant decrease in the level of 12
small cajal body-speciﬁc RNAs (scaRNAs) that direct the biochemical modiﬁcation of speciﬁc nucleotides in
spliceosomal RNAs. We sought to determine if scaRNA levels inﬂuence patterns of AS and heart development.
We used primary cells derived from the RV of infants with TOF to show a direct link between scaRNA levels
and splice isoforms of several genes that regulate heart development (e.g., GATA4, NOTCH2, DAAM1, DICER1,
MBNL1 and MBNL2). In addition, we used antisense morpholinos to knock down the expression of two scaRNAs
(scarna1 and snord94) in zebraﬁsh and saw a corresponding disruption of heart development with an accompanying alteration in splice isoforms of cardiac regulatory genes. Based on these combined results, we hypothesize
that scaRNA modiﬁcation of spliceosomal RNAs assists in ﬁne tuning the spliceosome for dynamic selection of
mRNA splice isoforms. Our results are consistent with disruption of splicing patterns during early embryonic
development leading to insufﬁcient communication between the ﬁrst and second heart ﬁelds, resulting in
conotruncal misalignment and TOF. Our ﬁndings represent a new paradigm for determining the mechanisms
underlying congenital cardiac malformations.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Congenital heart disease (CHD) accounts for 25% of all birth defects
and is a leading cause of death in children b 1 year of age [1]. Nearly
80% of all CHD cases are idiopathic and multiple lines of evidence indicate a genetic contribution to CHD, but only relatively limited progress
has been made in identifying the genetic basis of CHD [2,3]. Conotruncal
defects, such as tetralogy of Fallot (TOF), result from disruption in the
ﬂow of tissue-speciﬁc information between the ﬁrst and second heart
ﬁelds at approximately 20 days of gestation. In the developing embryo,
Abbreviations: AS, alternative splicing; CHDs, congenital heart defects; RV, right
ventricle; TOF, tetralogy of Fallot; scaRNAs, small cajal body-speciﬁc RNAs; CHD, congenital
heart disease; SHF, second heart ﬁeld; ncRNA, noncoding RNA; snRNAs, small nuclear RNAs;
snoRNAs, small nucleolar RNAs; rRNAs, ribosomal RNAs; TA, truncus arteriosus; PA/IVS, pulmonary atresia with intact ventricular septum; LNA, locked nucleic acid; qRT-PCR, quantitative RT-PCR; KUMC-MF, University of Kansas Medical Center-Microarray Facility; IPA,
Ingenuity Pathways Analysis; RMA, Robust Multichip Analysis; FDR, false discovery rate;
MOs, morpholino antisense oligos; hpf, hours post fertilization; RPKM, reads per kilobase
of exon per million mapped reads; SMN, survival of motor neuron; SMA, spinal muscular atrophy; RP, retinitis pigmentosa
⁎ Corresponding authors.
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precise spatial and temporal signaling is required between the ﬁrst
heart ﬁeld from which the left ventricle is derived and the second
heart ﬁeld (SHF) from which the right ventricle (RV) and conotruncal
outﬂow tract are derived [4–10]. Abnormal rotation of the SHF
causes conotruncal malformations such as TOF. Development of the
conotruncal outﬂow tract is mediated by multiple transcription factors
(e.g., NKX2.5, GATA4) and gene networks, including the Wnt and
NOTCH pathways. Although studies of the developing vertebrate heart
have provided a framework of regulatory control, they have failed to
deﬁne the underlying causes of the majority of CHDs.
The importance of noncoding RNA (ncRNA) for heart development
has recently been shown to depend on the correct spatiotemporal expression of particular microRNAs [11]. In addition, there are clear spatial
and temporal transcript splicing transitions that are conserved in the
vertebrate heart during fetal and postnatal development [12,13]. Some
exons are constitutive and are present in every mature message; however, there are many alternatively spliced genes/exons which are variably retained or excluded from a mature transcript that dramatically
increase the complexity of the transcriptome and thus the proteome.
Alternative splicing (AS) is temporally and spatially controlled resulting
in unique splice variants in different tissues and at different time points

http://dx.doi.org/10.1016/j.bbadis.2015.04.016
0925-4439/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in the same tissue. The transition from a fetal to postnatal pattern of a
conserved set of alternatively spliced isoforms was shown to be critical
for mouse heart development [14]. Clearly, mRNA splicing plays a significant role in mammalian cardiac development, but the potential contribution to human heart pathology remains unknown.
The spliceosome facilitates pre-mRNA processing of most primary
transcripts in eukaryotic genomes. The primary spliceosome, called
the U2 spliceosome, is a multimegadalton ribonucleoprotein complex
composed of numerous proteins and ﬁve small nuclear RNAs (snRNAs
or spliceosomal RNAs: U1; U2; U4; U5; and U6). The conformation
and composition of the spliceosome are highly dynamic and highly conserved across eukaryotes [15]. Elaborate RNA–RNA–protein interactions
align the reactive subgroups and repeatedly rearrange as each intron is
identiﬁed, intron–exon boundaries are located, and catalysis proceeds
to remove each intron in every pre-mRNA.
As snRNAs mature they are themselves biochemically modiﬁed in a
process directed by other small noncoding RNAs, the scaRNAs (small
cajal body-speciﬁc RNAs). The scaRNAs are a subset of the small nucleolar RNA (snoRNA) family, which is a large family of conserved ncRNAs
that primarily guide biochemical modiﬁcations of speciﬁc nucleotides
(e.g., methylation and pseudouridylation) of ribosomal RNAs (rRNAs)
and snRNAs. Without the speciﬁc modiﬁcations controlled by the
scaRNAs, the spliceosome fails to function properly [16]. While the biochemical targets of snoRNAs have been clearly elucidated over the last
20 years, there is a paucity of information regarding the developmental
signiﬁcance of this abundant class of ncRNA.
We previously detected 135 snoRNAs (including 12 scaRNAs) of
more than 900 snoRNA probes on an ncRNA array which were statistically differentially expressed in the right ventricles of infants with TOF
relative to controls [17]. Most of these snoRNAs (126, 93%) had
decreased expression. Remarkably, 115 (91% of 126 with reduced
expression) had similarly reduced expression in the fetal myocardium
relative to the control tissue [17]. Two snRNAs, U2 and U6, also had
reduced expression levels in TOF and fetal tissue relative to control
tissue. The 12 scaRNAs that were moderately reduced in TOF myocardium targeted only the snRNAs, U2 and U6. Furthermore, we observed
alternative splice isoforms of genes that were enriched in genetic pathways that are known to be critical for heart development. This suggests
the possibility of the failure of adequate regulation of the scaRNA level
early in gestation and a potential impact on spliceosomal function
through alteration of U2 and U6.
Studies of snoRNA-directed modiﬁcation of ncRNA in bacteria and
lower eukaryotes have shown that nucleotide modiﬁcations are important for stabilization, maturation, turnover and localization of ncRNAs
[18,19]. However, similar studies in vertebrates have not been described
until our recent report of the developmental signiﬁcance of snoRNAs in
zebraﬁsh [20]. Impaired rRNA modiﬁcation, even at a single site, led to
severe morphological defects and embryonic lethality in zebraﬁsh
which suggests that rRNA modiﬁcations play an essential role in vertebrate development. Our studies highlight the importance of posttranscriptional modiﬁcations and their role in ncRNA function in higher
eukaryotes. However, there are currently no reported studies of the
role that scaRNAs play in regulating vertebrate development. Here we
report the ﬁrst investigation of scaRNA regulation of spliceosomal function and vertebrate development.
2. Material and methods
2.1. Derivation of primary cells
Tissue samples were collected at the time of surgical correction of
TOF, truncus arteriosus (TA), and pulmonary atresia with intact ventricular septum (PA/IVS). All infants were less than one year of age and
cytogenetic testing veriﬁed that none of the subjects had 22q11.2 deletions. Informed consent was obtained from a parent or legal guardian
after reviewing the consent document and having their questions

answered (IRB # 11120627). Detailed subject descriptions were previously published [17,21]. Primary cell cultures were derived from RV tissue of infants with TOF. The RV tissue was immediately immersed in
DMEM (Invitrogen/Gibco, Grand Island, NY) plus 10% fetal calf serum
(Sigma/Safc, St. Louis, MO) and 1% penn/strep (Gibco). The tissue was
minced and most of the media was removed, leaving only enough to
keep the tissue from drying out. After 24 h, additional media was
added and cells were growing robustly after 3 to 4 days. Media was exchanged every 48 h. In addition, we obtained a primary neonatal cardiomyocyte cell culture derived from normally developing human neonatal
cardiac tissue from Celprogen (San Pedro, CA Cat#36044-21). These cells
were also grown in DMEM plus 10% fetal calf serum and 1% penn/strep.
2.2. Transfection of scaRNA plasmids into primary cells
The expression vectors pCGL-SCARNA4 (ACA26)and pCGLSCARNA1 (ACA35)were a generous gift from Dr. Tamas Kiss,
Universite Paul Sabatier [22]. The scaRNAs were cloned into an intron sequence between hemoglobin exons 3 and 4 so that they
would be correctly processed in vivo and expression was driven
with the CMV promoter. We replaced SCARNA1 with the corresponding
sequences from the scaRNAs:SNORD94, SCARNA8, SNORD67, and
SCARNA23. The scaRNAs were transfected into the primary cell lines
derived from infants with TOF according to the manufacturer's protocol.
Brieﬂy, 2 μg of plasmid DNA was diluted in 200 μl of serum free media
and added to 2 μl of the Poly Magnetofectant (a magnetic nanoparticle
transfection reagent; Oz Bioscience, France), vortexed and incubated
for 20 min at room temperature. The transfection mixture was added
dropwise to 2 × 105 cells in 1.8 ml of media containing 10% serum
in a single well of a 6 well plate. The culture plate was set on top of
a plate magnet (Oz Biosciences) for 20 min, and returned to the incubator. After 72 h, the cells were trypsinized, pelleted and stored at −80 °C
until processed for RNA extraction.
2.3. scaRNA knockdown
We used antisense LNA oligos (locked nucleic acid oligos, Exiqon
Life Sciences, Woburn MA) to suppress the scaRNAs in primary
cardiomyocytes as has been done previously in immortalized cell
cultures [23,24]. Brieﬂy, the LNA oligo protocol is as follows, 50 μM
LNA oligo in 100 μl serum free media is mixed with 12 μl HiPerfect transfection reagent (Qiagen, Valencia, CA) and incubated for 20 min at room
temperature. The transfection mixture was added to 2 × 105 cells in
2.3 ml of media with 10% serum in a single well of a 6 well cell culture
plate. After 48 h, the cells were pelleted and stored at − 80 °C until
processing. Identifying LNA oligos for effective knockdown of the
scaRNA was an empirical process. Two to four oligos were tested for
each scaRNA to determine which were most effective at knocking
down the target scaRNA.
2.4. RNA isolation and qRT-PCR (human tissue)
RNA was extracted from ~2 × 106 cells using a mirVana miRNA isolation kit (Invitrogen/Ambion) according to the manufacturer's instruction. Brieﬂy, an equal quantity of total RNA (1 μg) together with random
and oligo dT primers was reverse transcribed using Superscript III
(Invitrogen by Life Technologies, Carlsbad, CA) according to the
manufacturer's directions. Quantitative RT-PCR (qRT-PCR) was performed using Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) according to the manufacturer's directions as previously
described [21]. The reaction was carried out in an ABI7000system (Applied Biosystems, Foster City, CA) beginning with 10 min at 95 °C. The
intensity of the SYBR Green ﬂuorescence was measured at the extension
step of each cycle. At least three replicates were performed on each
sample for each gene. The primers for each scaRNA, snRNA and gene
are given in Table S1. A dissociation curve was generated for all
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reactions, and reactions were run on agarose gels to verify the presence
of a single band. Normalization of the qRT-PCR reactions used the
2(− ΔΔCT) method using RNU24 and GAPDH as the standardization
genes for each sample to correct for minor experimental error. Normalized CT values were averaged to produce the mean CT value. Primers for
the qRT-PCR validation of variably spliced exons in genes from the Wnt
pathway in zebraﬁsh morphants are provided in Table S2. The values
from the normally spliced exons were normalized using a constitutive
exon from within the same gene.
2.5. Microarray analysis of splice variants
The exon arrays were AffymetrixHuEx-1_0-st-v2. The raw data for
the arrays have been deposited in the Gene Expression Omnibus
(miRNA arrays accession No. GSE35490) as described previously [17].
All arrays were run at the University of Kansas Medical CenterMicroarray Facility (KUMC-MF) according to the manufacturer's
protocols. KUMC-MF is supported by the University of Kansas, School
of Medicine, KUMC Biotechnology Support Facility, the Smith Intellectual and Developmental Disabilities Research Center (HD02528), and the
Kansas IDeA Network of Biomedical Research Excellence (RR016475).
All statistical analyses were performed using statistical software: Partek
Genomics Suite software version 6.6 (Partek Inc), and Bioinformatic
assessment was done using Ingenuity Pathways Analysis (IPA, Ingenuity
Systems, Inc Redwood City, CA). Raw data (CEL. ﬁles) were uploaded
into Partek Genomics Suite for normalization and statistical analysis.
Robust Multichip Analysis (RMA) was used for background correction,
followed by quintile normalization with baseline transformation
to the median of the control samples. Only probes with intensity
values N 20% of background value, in at least1 of the conditions, were included for additional analysis. A Student t test with a Benjamini and
Hochberg multiple test correction for false discovery rate (FDR) was
used to determine signiﬁcance. Probes were ﬁltered using an FDRadjusted p value ≤ 0.05.IPA was used to assess networks, functions,
and/or canonical pathways represented by the list of alternatively
spliced genes. Fisher's exact test was used to identify the most signiﬁcantly (p ≤ 0.05) altered biological functions and/or disease categories
within the dataset.
2.6. Zebraﬁsh
Zebraﬁsh (Danio rerio, wild-type AB line) were raised and maintained under standard laboratory conditions at the Division of Bioresources, Frontier Science Research Center, University of Miyazaki,
Japan. We targeted orthologous scaRNAs in zebraﬁsh for knockdown
with antisense morpholinos designed to inhibit scaRNA processing as
previously described [20]. A database search for the 12 scaRNAs that
were reduced in TOF revealed that 7 have homologs in zebraﬁsh, including scarna1, scarna8, scarna13, scarna14 and scarna2 that carry out U2
snRNA modiﬁcations, and snord94 and snord7 which carry out U6
snRNA modiﬁcations. These “shared scaRNA targets” ensure the comparability and relevance of the data obtained from the zebraﬁsh experiments to human heart development. We chose to focus on two
scaRNAs scarna1 that targets U2 and snord94 that targets U6 as these
are representative scaRNAs that had an impact on snRNA function
when targeted in the human primary cell cultures.
2.7. Morpholino oligonucleotide injections and morphological analysis
Morpholino antisense oligos (MOs)to inhibit precursor scaRNA processing were obtained from Gene Tools, LLC (Philomath, OR, USA). The
scarna1 and snord94MOs were designed at the 3′ end of scaRNA within
the ﬁfth intron of ppp1r8b and second intron of rrm2 gene, respectively
(Fig. S1). As a control, morpholinos with ﬁve mispaired bases (misMOs)
were used. The sequences of the MOs are given in Table S3. Based
on our previous methods [25], the MOs were injected into the
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blastomere of one-cell stage embryos using an IM-30 Electric
Microinjector (Narishige, Japan) at the following concentrations:
snord94MO at 5 μg/μl; and scarna1MO at 10 μg/μl. The control MOs
were injected using the same volume. We examined the effects of
scaRNA suppression on heart development in zebraﬁsh embryos by microscopic observation. The morphology and physiological function of
zebraﬁsh heart in morphants were analyzed by live-video imaging.
2.8. Northern blot analysis
The total RNA was extracted using TRIzol Reagent (Invitrogen, USA)
according to the manufacturer's instructions. For each sample, 10 μg of
total RNA was separated on a 1.5% denaturing agarose gel and blotted
according to our previous procedures [20]. Brieﬂy, the blots were
hybridized overnight at 42 °C in modiﬁed Church–Gilbert hybridization
buffer (0.5 M NaHPO4, 1 mM EDTA, 0.5% BSA and 7% SDS) containing
1000 cpm LNA probes labeled with [γ-32P] ATP by T4 polynucleotide
kinase (Takara, Japan). The probe sequences are listed in Table S3.
2.9. Semi-quantitative RT-PCR
The total RNA was isolated from 24–25 h post fertilization (hpf)
embryos using a TRIzol Reagent method (Invitrogen, USA). Semiquantitative RT-PCR was performed with 0.5 μg of total RNA as a
template in a 20 μl reaction using a One-step RT-PCR kit (Qiagen,
Germany). The RT-PCR conditions are as described in the
manufacturer's protocol, except for a change in annealing temperature,
which depended on the Tm value of the primers. The primer sequences
for the genes are given in Table S3.
2.10. RNA-Seq analysis
Messenger RNA was extracted from zebraﬁsh embryos at 6 and
24 hpf from wildtype embryos and embryos injected with antisense
or mismatch morpholinos. Sequencing was done using an Illumina®
Genome Analyzer™. Single-end mRNA-Seq reads were mapped to the
zebraﬁsh genome (danRar7), allowing up to two mismatches, using the
STAR aligner and the Partek® Flow™ interface (Partek Inc. St. Louis,
MO). The output BAM ﬁles were imported directly into Partek
Genomics Suite 6.6 (PGS, Partek Inc. St. Louis, MO) and analyzed using
the RNA-Seq interface. To detect differentially spliced genes, mRNA
quantiﬁcation was performed using the reads per kilobase of exon per
Million mapped reads (RPKM) model for normalization [26]. Reads
were assigned to individual transcripts/exons of a gene based on the
Expectation/Maximization (E/M) algorithm [27] using the ENSEMBL
database. Never the less, annotation of the zebraﬁsh genome is limited
with respect to splicing variants, so extensive analysis of genome-wide
splicing was inadequate. We therefore focused on members of Wnt
pathway which is more extensively annotated and also critical for regulating heart development. We evaluated exon retention in those
genes using PGS ANOVA with a signiﬁcant p-value ≤0.05.
3. Results
3.1. Reduced noncoding RNAs and altered splicing patterns in primary cells
Our analyses of splicing variants in TOF myocardium using exon
microarrays revealed a substantial number of genes that had signiﬁcant
differences in the patterns of splicing isoform expression in the RV from
infants with TOF relative to the control RV. Furthermore, the genes with
signiﬁcant changes in isoforms were signiﬁcantly enriched in networks
known to be critical for regulating heart development {(i.e., Wnt,
NOTCH, Sonic Hedgehog, BMP pathways p b 0.01, Fig. 1), see [17] for
explanation of how cardiac list was derived}. Importantly, ~ 50% of
these alternative isoforms are present in similar ratios in normal fetal
RV relative to the RV of normally developing infants. Fig. 2 shows
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Fig. 1. Splicing variants detected in TOF RV vs. normal RV. Alternative splice variants in TOF RV are enriched in genes that are critical for heart development. Splicing analyzed using Partek
Genomic Suite analytical software (including Bonferroni correction). 1st number is genes with alternative isoforms, 2nd number is total # of genes in the group. **Signiﬁcantly different
from “all messages” p b 0.01. 1. Cardiac Websites used to derive list: Cardiovascular Gene Ontology Annotation Initiative; CHD Wiki; HuGE Navigator (version 2.0). 2. Derived from
Ingenuity Pathways Analysis.

representative examples of alternative splicing, DICER and DAAM1,
which have a similar pattern of splicing in fetal and TOF tissues (blue
and green lines) compared to the control tissue (red line).
We previously reported that 125 snoRNAs, including 12 scaRNAs,
were downregulated in RV from 16 infants with TOF [17] (the scaRNAs
are listed in Table 1 with their target nucleotides and known zebraﬁsh
homologs). In addition, U2 and U6 had signiﬁcantly reduced expression
in our 16 TOF RV samples compared to our 8 controls (analysis done by

microarray on 16 subjects; U2 was reduced 1.8 fold in TOF RV, p = 0.04,
and U6 was reduced 3.2 fold in TOF RV p b 0.0001). We analyzed U2 and
U6, and all 12 scaRNAs by qRT-PCR in the RV of an additional 24 samples
from infants with TOF and all were consistently and signiﬁcantly downregulated compared to the 8 controls (data not shown). In these same
24 RV samples, we also used primers targeting the alternatively spliced
exon (as shown in Fig. 2) to analyze by qRT-PCR the splicing of our six
index genes (GATA4, MBNL1, MBNL2, DICER, DAAM1 and NOTCH2)

3’

5’

Probe intensity relative to background

Exon expression

Dicer

PCR-Primers

3’

5’

PCR-Primers
Exon expression

DAAM1

Control

Fetal

TOF

Alternative splicing

Fig. 2. Alternative splicing of some key genes resembles a fetal pattern. Red lines and arrows show position of primers used to amplify alternatively spliced region. The top section of each
section shows known exons. The small boxes represent probe locations from the exon arrays. Bars around boxes are the standard deviation.
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Table 1
scaRNAs with reduced expression in the right ventricle of infants with TOF.
scaRNA name

Zebraﬁsh homolog

Target RNA and nucleotide(s) targeted

Chromosome

Start

Stop

Affy probeset ID

Subcomponent of SCARNA2
SCARNA9
SCARNA2
SCARNA8
SCARNA4
SCARNA1
SNORD7
SNORD8
SNORD9
SNORD67
SNORD94
SCARNA23
SCARNA9L

No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
No

U2 snRNA C61 and G11
U2 snRNA G19 and A30
U2 snRNA G25 and C61
U2 snRNA U34 and U44
U2 snRNA U41 and U39
U2 snRNA U89
U6 snRNA A47
U6 snRNA A53
U6 snRNA A53
U6 snRNA C60
U6 snRNA C62
U6 snRNA U40
U2 snRNA G19 and A30 (probable)

chr1
chr11
chr1
chr9
chr1
chr1
chr17
chr14
chr14
chr11
chr2
chrX
chrX

109643155
93454680
109642815
19063654
155895749
28160912
33900676
21865452
21860310
46783939
86362993
24762558
20154184

109643234
93455032
109643234
19063784
155895877
28161077
33900772
21865560
21860412
46784049
86363129
24762687
20154531

HBII-382_s_st
mgU2-19-30
mgU2-25-61_st
U92_st
ACA26_st
ACA35_st
mgU6-47_st
mgU6-53_st
mgU6-53B_st
HBII-166_st
U94_st
ACA12_st
scaRNA-9L

KIAA1731
FAM29A
KIAA0907
PPP1R8
CHD8
CHD8
CKAP5
PTCD3
POLA1
EIF1AX

that have all been previously reported and each isoform is known to
be protein coding. The diagrams illustrating the data extracted from
the browsers and the location of alternative spliced regions in our six
index genes are shown in Supplemental Figs. 2–7.

which are important for regulating cardiac development. These six
genes had clear changes in splicing based on our microarray analysis
of the right ventricle of all infants examined with TOF. Alternative splicing of the six index genes was highly consistent among the 24 additional
samples analyzed by qRT-PCR, each sample having the pattern seen in
the 16 samples analyzed by exon arrays.
Although it is beyond the scope of this report to extensively evaluate
the proteomic impact of the alternative isoforms we describe, we used
the UCSC and Ensemble Genome Browsers to examine the isoforms of
our six index genes. Our six index genes all have alternative isoforms

a

Host gene

3.2. Reduced scaRNAs, U2 and U6 expression, and alternative splicing are
not a consequence of hypertrophy
Hypertrophy is known to induce gene expression patterns similar to
those associated with fetal growth. To assess whether the altered
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SCARNA4
SCARNA1
SCARNA2 (HBII-382)
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*
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*
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*
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Fig. 3. scaRNA and splice variant levels in control and affected right ventricle.(A). scaRNA and spliceosomal RNA levels in fetal TOF, TA and PA/IVS RV relative to control RV. Splicing variant
assessed by qRT-PCR using primers speciﬁc to the variable exon. N = Control — 7, TOF — 31, Fetal — 6, TA — 3, PA/IVS — 3. *Signiﬁcantly different from control, p b 0.05. (B). Variable exon
splicing in RV tissue assessed by qRT-PCR using exon speciﬁc primers. Splice isoforms of index genes are similar in TOF and TA and fetal tissue, but PA/IVS does not differ from the control.
N = Control — 7, TOF — 31, Fetal — 3, TA — 3, PA/IVS — 3. *Signiﬁcantly different from control, p b 0.05.

1624

P. Patil et al. / Biochimica et Biophysica Acta 1852 (2015) 1619–1629

expression and splicing observed in the RV of infants with TOF were a
consequence of hypertrophy, we used qRT-PCR to assess the expression
of U2 and U6, our 12 scaRNAs and the alternative splicing of our six
index genes in RV samples from three infants with TA and three infants
with PA/IVS. Both TA and PA/IVS are commonly associated with hypertrophy, as is TOF; however the three conditions may have different
embryological origins. The qRT-PCR analysis of PA/IVS and TA samples
indicated that U2 and U6 levels were not reduced in PA/IVS relative to
the control tissue, but were signiﬁcantly reduced in TA, similar to TOF
relative to control RV. Furthermore, while none of the scaRNAs had
changed expression in the PA/IVS-RV, they were all reduced in the
TA-RV (Fig. 3A). Finally we assessed alternative splicing in our six
index genes in PA/IVS and TA. The splice isoforms were unchanged
relative to the controls in PA/IVS, while in TA-RV alternative splicing
patterns were essentially the same as in TOF-RV (Fig. 3B). While this
is not a transcriptome assessment, these data indicate that the changes
we saw in snRNAs, scaRNAs and splicing in the TOF and TA samples
were not simply a consequence of hypertrophy as they were not present in the PA/IVS samples which were also hypertrophic.
3.3. Alternative splicing occurs primarily in U2 type exons compared to U12
type exons
The spliceosomal RNAs, U2 and U6 are part of the U2 spliceosome,
but there is a secondary spliceosome, termed U12, that is structurally
and functionally analogous to the U2 spliceosome but does not use the
U2 and U6 snRNAs [28]. The U12 spliceosome mediates the excision of
a minor class of evolutionarily conserved introns that have noncanonical recognition sequences that are distinct from those recognized
by the U2 spliceosome. The U12 spliceosome accounts for approximately 0.5% of exon/intron splicing. We used the U12 database (U12DB at
http://genome.imim.es/cgi-bin/u12db/u12db.cgi.) to identify genes
that contain exons with U12 splicing recognition sequences. We used
our exon array data (GEO # GSE35490) to compare the frequency of
alternative splicing between U2 and U12-targeted exon/introns in the
myocardium from normally developing infants and infants with TOF.
Of the 229 genes in the ﬁve networks associated with heart development found on our exon arrays from our TOF-RV samples, 117 (51%)
had signiﬁcantly altered splicing patterns, of which N25% were in common with fetal tissues compared to RV from normally developing infants. We found 464 genes with U12 type exons on our array and
22(4.8%) of them had signiﬁcant alternative splicing events in TOF myocardium. These two proportions (51% vs. 4.8%) are signiﬁcantly different
(p b 0.0001) indicating that splicing variation was signiﬁcantly higher in
U2 type exons compared to U12 type exons in myocardium from infants
with TOF. In addition, the 464 genes with U12 intron/exon junctions
had 1191 exons/introns targeted by the U12 spliceosome, of which
26 exons/introns were alternatively spliced (2.2%). The 229 genes
from the ﬁve cardiac networks had 3429 exon/intron units of which
408 were alternatively spliced (12%).
3.4. Primary cells derived from TOF myocardium retain the same relative
splicing and expression patterns as the tissue
We derived primary cell lines from right ventricular myocardium
obtained from 10 infants with TOF (TOF primary cells, referred to after
this as TOFpcs). We extracted RNA from the TOFpcs and examined expression patterns of scaRNAs, spliceosomal RNAs and mRNA splicing
from the six index genes that were alternatively spliced in TOF RV tissue
(Table 2). TOFpcs retained the same fetal type pattern of scaRNA and
spliceosomal RNA expression relative to cells derived from normally
developing neonatal cardiac primary cells. Splicing patterns also
remained similar in the TOFpcs relative to the tissue they were derived
from. Table 2 shows examples of qRT-PCR assessment of alternatively
spliced isoforms (a measure of retained fetal exons) in the index
genes from two independently derived TOFpcs compared to cells

Table 2
Fetal splice isoforms are overexpressed in TOF myocardium and in TOF primary cells
(qRT-PCR, fold change in fetal exons).
Normal
TOF
Normal primary TOFpc31 TOFpc44
Gene
myocardium myocardium cardiomyocyte
(exon of
cells
fetal isoform)
DICER
DAAM1
GATA4
NOTCH2
MBNL1
MBNL2

1
1
1
1
1
1

+2.8
+4.8
+10.0
+4.3
+6.7
+8.4

1
1
1
1
1
1

+2.6
+3.0
+8.8
+6.0
+17.9
+9.5

+4.6
+3.9
+13.2
+20.8
+26.5
+12.1

derived from normally developing heart tissue. In addition, the splicing
and expression patterns were evaluated in the other eight independent
cell lines and all were consistent.
3.5. Overexpression and knockdown of scaRNAs in primary cells cause
changes in splicing
In order to investigate whether the alternative splicing we demonstrated in tissues and cells derived from patients with TOF was a consequence of changes in levels of scaRNAs, we used the expression
plasmids pCGL-SCARNA4 and pCGL-SCARNA1to induce expression of
the respective scaRNAs in primary cells derived from infants with TOF.
When either plasmid was transfected alone there was an increase
in the scaRNA but no change in U2 level (the snRNA targeted by
SCARNA4and SCARNA1) nor any change in other spliceosomal RNAs,
and no detectable change in splicing (data not shown). However,
when we simultaneously transfected plasmids pCGL-SCARNA4 and
pCGL-SCARNA1 into TOF primary myocytes, there was a modest (~1.8
fold) but signiﬁcant upregulation in the amount of U2 (Fig. 4A). There
was no change in the level of U6 or any other spliceosomal RNA tested.
Importantly, there was a signiﬁcant reduction in the level of the fetal
type splice forms in the index genes (Fig. 4B). These experiments
were repeated in primary cells derived from the RV of three different infants with TOF (three different genotypes). Fig. 4 compares transfected
TOF cells to nontransfected TOF cells and normal cells. We transfected
single plasmids in concentrations equal to the total plasmid concentration used in double transfections and saw a dose response in the
amount of scaRNA in the single plasmid transfection but no change in
splicing or target spliceosomal RNA level or cell viability (data not
shown). Thus the affect seen by dual plasmid transfection appears
to be the consequence of synergistic effect and not due to plasmid
overload.
We knocked down single scaRNAs (SCARNA1 and SCARNA4)
in cardiomyocytes from normally developing infants. The targeted
scaRNAs were reduced but single knockdown experiments did not
affect U2 levels or splice isoform levels (data not shown). This is not
surprising as multiple scaRNAs probably need to be targeted to have a
signiﬁcant downstream impact, as we saw with upregulation of the
scaRNAs. When we knocked down both SCARNA1 and SCARNA4 simultaneously, we saw a modest but signiﬁcant decrease in the level of U2
(~65%, p b 0.001) with no change in U6 level (performed on two independent cell lines). In addition, after knocking down both scaRNAs we
saw changes in splicing of some of our index genes, but the changes
were not necessarily the same as the splicing patterns observed in the
TOF tissue.
3.6. scaRNA levels and splicing patterns change during
zebraﬁsh development
There is little known about alternative splicing of mRNA during
zebraﬁsh development. Therefore, we downloaded RNA-Seq data from
the Gene Expression Omnibus derived from developing zebraﬁsh
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Normal primary
myocytes

TOF Primary
cells
TOF cells after
overexpression of
SCARNA4 and
SCARNA1

Fig. 4. A. U2 level increase after overexpression of scaRNAs. Data are fold change, averaged
from three different primary myocyte cell lines. *Signiﬁcant difference, p b 0.01,
**p b 0.001. The level of spliceosomal RNAs, U2 and U6, are signiﬁcantly lower in primary
cells from TOF compared to normal cardiomyocytes. U2 is signiﬁcantly increased in primary cells from TOF after transfection with the both scaRNA expression plasmids containing
ACA26 and ACA35 compared to normal cardiomyocytes, while U6 is unchanged. U2 and
U6 levels were unchanged after transfection with single plasmids with total plasmid concentration equal to the combined plasmid concentration of double transfections. Data not
shown. B. Fetal splice isoforms are reduced after overexpression of scaRNAs. Data are fold
change, averaged from three different primary myocyte cell lines. *Signiﬁcant difference
between primary cells with over expressed scaRNAs vs TOF primary cells, p b 0.05. Expression plasmids pCGL-SCARNA4 and pCGLSCARNA11, 2 were a generous gift from Dr. Tamas
Kiss, Universite Paul Sabatier, France.

embryos at 0.75 h, 6 h, 1 day, 2 days, 3 days and 5 days post fertilization
(GEO#: GSE30603) and analyzed it for alternative splicing and changes
in scaRNA expression during normal developmental progression in
zebraﬁsh. We reanalyzed the ﬁles to identify snoRNA and scaRNA sequences within the data. We identiﬁed 74 snoRNAs and scaRNAs within
the zebraﬁsh genome. Many snoRNAs varied signiﬁcantly over the developmental time course (Fig. S2). We were particularly interested in
scarna1 and snord94 since they inﬂuenced the spliceosomal RNA levels
in our experiments using human primary cells. Their expression patterns varied dramatically as development progressed (Fig. S9A and B).
Although, the current knowledge regarding splice variants within the
zebraﬁsh genome is only rudimentary, we found clear changes in ratios
of splice isoforms of many of genes, including genes that are important
for heart development (representative examples: gata4, Fig. S10 and
dicer, Fig. S11).
3.7. Inhibition of scaRNA expression alters heart morphology and splicing
in zebraﬁsh
We inhibited the scaRNA expression in zebraﬁsh using precursorMO, which inhibits scaRNA precursor processing and thus reduces the
level of the mature scaRNA [20]. The MOs were designed to target the
precursor sequence of the scaRNAs (snord94 and scarna1) located
within the introns of gene (Fig. S1). Loss of scaRNA expression was
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conﬁrmed by northern blot analysis of total RNA that was extracted
from MO-injected embryos (MO, Fig. 5). Northern blot analysis showed
a decrease in mature snord94 expression with the snord94 MO, but
mature scarna1 expression is unaltered in these morphants. This
demonstrates that the snord94 MO speciﬁcally inhibited snord94
scaRNA synthesis (Fig. 5A). Similarly, scarna1 synthesis is speciﬁcally
suppressed in scarna1 MO injected embryos. In addition, semiquantitative RT-PCR analysis revealed that scaRNA precursor inhibition
using either snord94 or scarna1 MO did not affect the host gene splicing
in morphants (Fig. 5B). In addition, RNA-Seq data also supported the
loss of scarna1 and snord94 when targeted by antisense morpholinos
as each was undetectable at 24 h when targeted (Figs. S12 and S13,
respectively).
We performed the phenotypic analysis of scaRNA-deﬁcient embryos
at various stages of development. Loss of scaRNA expression resulted in
growth impairment and speciﬁc developmental abnormalities, primarily involving heart malformations. At 25 hpf, both the scarna1 and
snord94 MO-injected embryos showed little developmental delay
with slightly changed eye and head size, and bent tail (Fig. 6A). However,
there were no defects in the brain, notochord, otic vesicles and ﬁns, except
the deformed yolk sac and pericardial edema, were more conspicuous at
50 hpf compared to uninjected embryos (Fig. S8). There were obvious
changes in the shape and size of the heart leading to its malformation, that was more signiﬁcant in morphants by 72 hpf (Fig. 6B and
Fig. S14 and Supplemental videos). The control mismatch MO-injected
embryos developed normally with no discernable differences compared
to uninjected embryos.
We analyzed splicing using RNA-Seq in zebraﬁsh at 6 hpf and 24 hpf
in wildtype, and after injection of antisense and missense morpholinos
at the one cell stage. The annotation of the zebraﬁsh genome is rudimentary for RNA-Seq assessment, especially with respect to splicing
variation. We therefore, focused on the Wnt pathway for assessment
of alternative splicing due to its being a key pathway for regulating
heart development and because it is currently more fully annotated in
the zebraﬁsh genome. We saw clear evidence of alternative exon inclusion or exclusion after antisense morpholino injection for 13 of the 39
Wnt pathway genes that are identiﬁable in the zebraﬁsh genome in
the UCSC genome browser. We used qRT-PCR to validate the Wnt pathway members with altered exon retention, as well as, gata4 and mbnl1
(Fig. 7A–D and Fig. 8). The qRT-PCR values of variable exons were
normalized to constitutive (nonvariable) exons from within the same
gene. Table S2 lists the qRT-PCR primer sequences used for validation.
We used qRT-PCR to examine these same 13 genes in the snord94 MO
morphants (Fig. S15). Although the pattern of change was not exactly
the same, 12 of the 13 Wnt genes had altered splicing patterns in the
snord94 MO morphants as well.
4. Discussion
4.1. Hypertrophy is not the cause of altered expression or splice variants
Coordinated control of alternative splicing modiﬁes the transcriptome and increases the complexity of the proteome during most
developmental processes [29,30].Studies of animal models have
shown the importance of appropriate splicing for proper heart development [8,12,31,32]. Still, knowledge of the sequence of events leading to
tissue speciﬁc alternative splicing is incomplete. We previously identiﬁed alterations in mRNA splice isoforms and in scaRNA expression patterns associated with tetralogy of Fallot [17]. In addition, these patterns
resembled patterns we observed in fetal heart tissue. It has been shown
that hypertrophy can reactivate genes that are expressed during fetal
development. We analyzed scaRNA expression and splicing patterns of
key index genes that regulate heart development in the RV of infants
with PA/IVS and TA to determine if hypertrophy could be reactivating
a fetal pattern of ncRNA expression and/or splicing. The embryological
origin of TOF and TA may share some common features involving the
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Fig. 5. Reduced expression of snord94 and scarna1 in MO-injected zebraﬁsh. (A). Northern blot analysis of total RNA extracted from MO-injected embryos. B. Semi-quantitative PCR of host
gene mRNA using either snord94MO or scarna1MO or mismatch morpholinos.

ﬁrst and second heart ﬁeld; however, PA/IVS is clinically distinct from
TOF or TA and probably has a distinctly different etiology. Importantly
hypertrophy is associated with all three developmental defects. In RV
from infants with PA/IVS, we saw no change in scaRNA levels (only 10
snoRNAs had signiﬁcant changes), nor any change in splicing compared
to RV from normally developing infants. However, all 12 scaRNAs examined and the splicing patterns of our index genes in the RV from infants
with TA were signiﬁcantly altered compared to controls and were
essentially the same as samples from infants with TOF as well as the

fetal pattern. This strongly suggests that the changes we saw in scaRNA
expression and alternative splicing are not due to reactivation of fetal
expression patterns as a consequence of hypertrophy.
4.2. Exons spliced by the U2 spliceosome are impacted by scaRNA
expression changes
Furthermore, we assessed the speciﬁcity of the scaRNA dysregulation
in our TOF samples by comparing splicing of exons/introns targeted by

Fig. 6. Heart deformities in MO-injected zebraﬁsh. (A) Lateral views of wild-type and MO-injected embryos at 25 and 50 hpf. Both the snord94 and scarna1 morphants display little
developmental delay with bent tail (black dotted curved line) and improperly formed yolk extension (black solid line) at 25 hpf. The pericardial edema (black triangle) and deformed
yolk sac were more evident at 50 hpf. (B) Enlarged images of the heart region in wild-type and MO-injected embryos at 72 hpf. The conspicuous pericardial edema (black dotted circle)
was observed in snoRNA MO-injected embryos. Gray outline is the atrium, blue outline is the ventricle. Scale bars: 200 μm.
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Fig. 7. Representative examples of splice isoform variation (exon retention) after treating zebraﬁsh embryos with anti-scarna1 morpholino. Each point on the horizontal axis represents an
exon and the value represents the mean RPKM (reads per kilobase per million) for that exon. Gata4 and Mbnl1, 6 and 24 h post fertilization (hpf).

the U2 spliceosome compared to those targeted by the U12spliceosome.
A small percentage (4.8%) of U12 targeted splice sites were altered in the
RV of infants with TOF when compared to the RV of normally developing
infants. However, this was signiﬁcantly less than the general group of
genes processed by the U2 spliceosome. An even greater difference was
seen in the splicing pattern of genes known to participate in regulating
heart development, in which 51% had alternative forms present in the
infants with TOF (signiﬁcance p b 0.0001 compared to 4.8% of genes processed by U12). There may have been other factors affecting splicing, but
these data suggest that the reduced expression of these scaRNAs did not

simply cause random changes in exon retention/exclusion and supports
the possibility of targeted effects on the spliceosome resulting in speciﬁc
alternative splicing.
4.3. Altered expression of scaRNAs causes changes in splicing
We used primary cells derived from the RV of infants with TOF to
study the effects of altered expression levels of speciﬁc scaRNAs on
the spliceosomal RNA they targeted and on splicing. Transfection of a
single scaRNA expression vector resulted in a signiﬁcant increase in
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Fig. 8. Splice isoform changes after targeting scarna1. Treating zebraﬁsh embryos with anti-scarna1 morpholino causes changes in exon retention of cardiac regulatory genes. 13 of 39
members of the Wnt family have signiﬁcant changes in exon retention after treatment with antisense morpholino (assessed by RNA-Seq and qRT-PCR, values shown are from qRT-PCR
data quantifying the variable exon). The misMO oligo is a negative control that differs from the primary morpholino by 5 nucleotides in the critical binding site. The gene name is
shown on the horizontal axis and the numbers represent the start position of the exon. *Signiﬁcantly different from the WT, p b 0.05.
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the level of that scaRNA but no signiﬁcant change in the targeted
spliceosomal RNA or in splicing of the index genes. However, when
two scaRNAs were transfected together (e.g., SCARNA1 and SCARNA4),
we saw a signiﬁcant increase in the targeted spliceosomal RNA (i.e., U2)
and an accompanying change in splice isoforms of our index genes. It
was fortuitous that combining expression vectors for SCARNA1 and
SCARNA4 had a signiﬁcant effect on U2 levels and a concomitant effect
on splicing. This is possibly because their target nucleotides are near
the catalytic site so this might result in a more dramatic impact on the
function of U2. In addition, SCARNA4 targets two nucleotides in U2
(uridine 39 and uridine 41) so modiﬁcation of a total of three nucleotides would be affected by expression changes of these two scaRNAs.
The change in isoform level reﬂected a change toward the normal postnatal form of the index genes. Additionally, we saw no change in the
level of any other spliceosomal RNAs (e.g., U1, U4, U5, U6 and U12)
after co-transfection of SCARNA1 and SCARNA4. This suggests that
these effects are speciﬁc and modiﬁcation of multiple nucleotides is
required in order to have measureable effects on snRNA stability or
function. Conversely, knockdown of scaRNAs using antisense oligos in
primary cell cultures derived from normally developing heart tissue
resulted in changes in the level of the targeted spliceosomal RNA
when two scaRNAs were changed, but the change resulted in changes
in exon retention of our index genes but not the same splice isoform
pattern as in tissue with reduced scaRNAs (RV of infants with TOF).
The changed levels of targeted spliceosomal RNA after simultaneous alteration of scaRNA level suggests a coordinated regulatory mechanism
that may be very intricate. Further studies are needed to delineate the
relative importance for spliceosomal function of individual scaRNAs, as
well as synergy among scaRNAs.
4.4. scaRNA levels and splice isoforms change during normal
zebraﬁsh development
In the last decade, the zebraﬁsh has been developed into an excellent
animal model system to study cardiovascular disease and development,
primarily because zebraﬁsh embryos are not completely dependent on
a functional cardiovascular system during embryonic development. In
addition, the optical transparency of zebraﬁsh embryos makes it easy
to follow the course of cardiovascular development [33]. In our previous
study, we successfully demonstrated for the ﬁrst time that impaired
rRNA modiﬁcations caused by the loss of expression of several snoRNAs
lead to severe developmental defects in zebraﬁsh [20]. Here we focus
our attention on scaRNAs targeting spliceosomal RNAs. Nothing is
known about the impact of these noncoding RNAs in the regulation of
vertebrate development.
As a starting point, we extracted transcriptome data from the GEO
and reanalyzed it to examine scaRNA expression patterns and to assess
splicing transitions during the ﬁrst ﬁve days of zebraﬁsh development.
There were signiﬁcant changes in expression levels of multiple scaRNA
during the time course examined. In addition, there were clear transitions in splicing of key genes that regulate heart development. Taken
together, these observations are consistent with the possibility that
scaRNA expression level and splicing transitions could be linked during
zebraﬁsh development.
4.5. Knockdown of scaRNAs alters splicing and heart development
in zebraﬁsh
Dysregulation of alternative splicing has been associated with the
regulation of heart development [8,34], cardiovascular diseases [35]
and several other diseases, including cancers [36]. Deﬁciency of the
snRNP assembly factor SMN (survival of motor neuron) in a zebraﬁsh
model of spinal muscular atrophy (SMA) resulted in tissue-speciﬁc
defective splicing of neurexin2aand motor axon defects [37,38]. The
mutations in the tri-snRNP subunit of the pre-mRNA splicing machinery

are linked to a hereditary eye disease, retinitis pigmentosa (RP). The
silencing of RP-associated splicing factor prpf31 in zebraﬁsh caused speciﬁc defects in vision, photoreceptor morphology and retinal gene expression [39]. However, there have been no studies targeting the RNA
components of the spliceosome and their potential impact on splicing
and development in vertebrates. Recently, we have reported the
developmental signiﬁcance of snoRNAs in zebraﬁsh by suppressing
the expression of several snoRNAs including snord26 (U26) snoRNA
[20], which was also downregulated in the myocardium of infants
with TOF [17].
In this study, we have shown that speciﬁc heart defects occur after
interfering with the maturation of scaRNAs by antisense morpholino
oligos. We conﬁrm that these speciﬁc defects are due to the scaRNA
suppression and its effect on altered splicing of cardiac genes. These
defects do not appear to be due to an off-target effect of host gene depletion, because of the detection of properly spliced ppp1r8b and rrm2
mRNA transcripts in both MO and misMO injected embryos. Our previous experiments targeting snoRNAs (that target ribosomal RNAs) in
zebraﬁsh produced parallel results in that speciﬁc phenotypes were
associated with the inhibition of speciﬁc snoRNAs [20]. The altered
splicing of cardiac genes (e.g., gata4, mbnl1,Wnt pathway genes)
might be due to the impaired 2′-O-methylation and pseudouridylation
modiﬁcations on spliceosomal RNA (snRNA) caused by the inhibition
of scaRNA expression. The scaRNAs targeted in our study, scarn1 and
snord94, direct pseudouridylation modiﬁcation on U2 snRNA (U89)
and 2′-O-methylation modiﬁcation on U6 snRNA (C62), respectively.
Although not identical, the changes in splicing we observed in 13 members of the Wnt pathway when either scarna1 or snord94 was targeted
in zebraﬁsh embryos were similar. Perhaps the close interaction between U2 and U6 during spliceosomal function results in a similar effect
on splicing ﬁdelity when the biochemical composition of either one is
altered but this remains to be examined in future investigations.
One limitation of this study is that we have not conﬁrmed the
scaRNA inhibition that resulted in the modiﬁcation of the speciﬁc target
nucleotide in the spliceosomal RNA. However, based on our previous
study these new ﬁndings are consistent with the concept that speciﬁc
defects in the splicing of cardiac genes and heart development are
derived from the impaired snRNA modiﬁcations in the zebraﬁsh
morphants. Our results indicate that dysregulated scaRNA expression,
even a single scaRNA, could lead to the failure of efﬁcient maturation
and function of the target spliceosomal RNA altering the spliceosome's
ability to efﬁciently process RNA contributing to defective organ
development.
Clearly, these new ﬁndings raise additional questions. The complex interaction of multiple scaRNAs and the cumulative impact on
spliceosomal ﬁdelity needs to be more extensively evaluated. However, by analyzing the transcriptome of the RV of infants with TOF,
we have identiﬁed a novel mechanism that contributes to regulatory
control of the spliceosome. Our data suggest that scaRNA expression
levels provide a regulatory mechanism that ﬁne tunes spliceosome
function by regulating the extent of biochemical modiﬁcation of
spliceosomal RNAs. During the maturation of spliceosomal RNAs,
scaRNAs may regulate spliceosomal RNA stability and/or target
speciﬁcity. We hypothesize that scaRNA expression level is tissue
speciﬁc and if dysregulated, particularly if multiple scaRNAs are
simultaneously altered, there is failure of efﬁcient maturation or
function of the snRNAs resulting in alteration in the ﬁdelity of the
spliceosome. This could in turn lead to poor transitions between
mRNA splice isoform patterns during organ development. Taken in
total, our observations suggest that scaRNAs modify spliceosomal
RNAs in a manner essential for temporal and/or spatial integrity of
spliceosome function. Thus, cardiac speciﬁc dysregulation of scaRNAs
could result in reduced efﬁciency or ﬁdelity of the spliceosome, leading
to inaccurate splicing causing ineffective communication between the
ﬁrst and second heart ﬁelds and resulting in defects in the conotruncal
outﬂow track, i.e., tetralogy of Fallot.
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